US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE PHARMA GROUP

23.04

+1.748.19%

Post-market: 23.040.00000.00%17:47 EDT

Volume:3.75K

Turnover:86.49K

Market Cap:2.15B

PE:-11.64

High:23.14

Open:23.12

Low:22.89

Close:21.30

52wk High:48.45

52wk Low:17.56

Shares:93.33M

Float Shares:71.58M

Volume Ratio:0.53

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9795

EPS(LYR):-0.7356

ROE:-154.56%

ROA:-23.02%

PB:11.21

PE(LYR):-31.32

Loading ...

Overview Company News Filings

Ascentage Pharma Gets FDA's IND Clearance for APG-3288

MT Newswires Live

Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director

CICC Maintains "Outperform" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options

Hong Kong Stock: ASCENTAGE-B Rises Over 3%

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Ascentage Pharma initiated with a Buy at Truist

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAPG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":23.04,"timestamp":1774641600000,"preClose":21.296,"halted":0,"volume":3750,"hourTrading":{"tag":"盘后","latestPrice":23.04,"preClose":23.04,"latestTime":"17:47 EDT","volume":16,"amount":367.2,"timestamp":1774648059850,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.08189331329827197,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"Market Closed","change":1.744,"latestTime":"03-27 16:00:00 EDT","open":23.12,"high":23.14,"low":22.89,"amount":86490.0825,"amplitude":0.011739,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":21.296,"postHourTrading":{"tag":"盘后","latestPrice":23.04,"preClose":23.04,"latestTime":"17:47 EDT","volume":16,"amount":367.2,"timestamp":1774648059850,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.526198},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-23.02%","roe":"-154.56%","lyrEps":-0.735552,"volumeRatio":0.526198,"shares":93330405,"dividePrice":0,"high":23.14,"amplitude":0.011739,"preClose":21.296,"low":22.89,"week52Low":17.555,"pbRate":"11.21","psRate":"25.85","week52High":48.45,"institutionHeld":0,"latestPrice":23.04,"eps":-1.979486,"divideRate":0,"volume":3750,"delay":0,"ttmEps":-1.979486,"open":23.12,"prevYearClose":26.24,"prevWeekClose":19.11,"prevMonthClose":24.1,"prevQuarterClose":26.24,"fiveDayClose":19.11,"twentyDayClose":24.1,"sixtyDayClose":26.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"AAPG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"Post Market","dateTimestamp":1774411200000,"actualEps":null},{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1764907200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-03-27","current":-11.639385,"percent":0.982877,"low":-76.454813,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"high":-11.627475,"avg":-30.301978,"sd":16.597696,"marketCap":2161491459.44},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44},{"date":"2026-03-13","current":-12.688953,"twenty":-40.378179,"median":-26.74375,"eighty":-16.137082,"marketCap":2141399622.46},{"date":"2026-03-20","current":-11.937263,"twenty":-39.521832,"median":-25.944924,"eighty":-15.566094,"marketCap":2005434649.33},{"date":"2026-03-27","current":-12.020857,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"marketCap":2161491459.44}],"updateTime":1774771665333},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601314871","title":"Ascentage Pharma Gets FDA's IND Clearance for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601314871","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601314871?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:12","pubTimestamp":1767780754,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group (AAPG) said late Tuesday it has received an investigational new drug clearance from the US Food and Drug Administration for oncology drug candidate APG-3288.The company plans to advance the drug into a phase 1 trial in patients with relapsed/refractory B-cell malignancies.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","LU2125909759.SGD","AAPG","BK4139","APG","LU2125909916.SGD","BK4129","LU1923622291.USD"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","AAPG","BK1161","BK1574","BK4139","APG","LU2125909916.SGD","BK4129","LU1923622291.USD","06855"],"gpt_icon":0},{"id":"2601479768","title":"Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601479768","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601479768?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has receivedinvestigational new drug (IND) clearancefrom the U.S. FDA, marking another major expansion to the comp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214213/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-U-S-Food-and-Drug-Administration-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU2125910336.SGD","LU1923621640.USD","LU2413666699.HKD","LU0472753341.HKD","LU0689626769.HKD","LU1939255532.USD","BK4588","LU2240825500.USD","LU1974910355.USD","LU1430594728.SGD","LU2125909759.SGD","LU1712237335.SGD","LU2041044095.USD","LU0069063385.USD","LU2089279066.USD","LU0511384066.AUD","LU1585245621.USD","LU1892829315.USD","BK4139","LU2238339852.HKD","BK4534","LU2125909916.SGD","APG","LU0289961442.SGD","IND","PK","LU1923622291.USD","LU1917777945.USD","LU1623119135.USD","LU2023250504.SGD","LU2125910179.SGD","BK4533","LU2362540622.SGD","LU2355687059.USD","LU0124676726.USD","LU1989772840.SGD","BK4585","LU0347712357.USD","BK4181","BCR","LU2229751404.USD","LU2308191902.HKD","WM","BK4129","LU2362541513.USD","LU0289739343.SGD","LU2211814178.USD","BK4120","AAPG"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1161","06855","BK1574","BK4139"],"gpt_icon":0},{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1574","AAPG","BK4139","BK1161"],"gpt_icon":0},{"id":"2590677273","title":"ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590677273","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590677273?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapyMolecular responses continue to deepen with extended treatment duration, reaching 60% m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","LU2463526074.USD","LU1261432733.SGD","BK4109","CP","AAPG","BK4585","BK4016","BK4588","BK4139"],"gpt_icon":0},{"id":"2590367742","title":"ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367742?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patient","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4161","LU0985320562.USD","ASH","AAPG","BK4533","BK4109","ALL","BK4585","III","BK4081","LU2463526074.USD","LU2355687059.USD","BK4588","LU1571399168.USD","LU1699723380.USD","BK4107","CR","BK4139","BK4134"],"gpt_icon":0},{"id":"2590367726","title":"ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367726?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4016","ASH","LU2463526074.USD","LU1261432733.SGD","CP","BK4077","BK4588","BK4109","CHR","AAPG","BK4139"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","ORR","OS","BK4097","LU2463526074.USD","AAPG","HR","BK4225","BK4139","ASH","BK4109"],"gpt_icon":0},{"id":"2589066826","title":"Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589066826","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589066826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 23:15","pubTimestamp":1765034100,"startTime":"0","endTime":"0","summary":"Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4109","BK4203","BK4225","LU2463526074.USD","BK4139","BK4107","HR","BK4117","ORR","TLS","ASH","BK4097","AFG"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1161","06855","BK1574","BK4139","EMA","BK4081"],"gpt_icon":0},{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4588","AAPG","BK4533","BK1161","LU0985320562.USD","EMA","BK4134","LU1699723380.USD","BK4139","BK4107","LU1571399168.USD","LU2355687059.USD","06855","BK1574","BK4081","ALL","BK4585"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494708.USD","ASH","IE00B3PB1722.GBP","LU1599440770.SGD","LU0234572021.USD","ALL","LU1066051225.USD","BK4134","BK4020","BK4161","LU1880398471.USD","LU1244550577.SGD","LU1674673428.USD","III","LU0234570918.USD","SG9999015986.USD","AAPG","IE00BFMHRM44.USD","LU1244550221.USD","LU2237443382.USD","LU2506952097.USD","BK4579","BK4139","CR","LU0985320562.USD","IE00BFXG1179.USD","LU1929549753.HKD","LU0868494617.USD","IE00BZ1G4Q59.USD","EMA","LU0348723411.USD","BK4581","BK4585","LU0792757196.USD","LU1894683348.USD","CDE","LU1221951046.USD","LU1571399168.USD","BK4017","LU0203347892.USD","LU1778281490.HKD","LU2286300806.USD","BK4560","BK4525","LU1221951129.SGD","IE00BDGV0183.EUR","IE00BVYPNW00.USD","OS","CSCO"],"gpt_icon":0},{"id":"2588720594","title":"Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720594","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720594?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196956/0/en/Ascentage-Pharma-to-Host-Webcast-Highlighting-Key-Data-from-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4181","BK4218","BK4109","BK4585","BK4588","ASH","LU2463526074.USD","BK4139","AAPG"],"gpt_icon":0},{"id":"1195526525","title":"ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1195526525","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195526525?lang=en_us&edition=fundamental","pubTime":"2025-11-27 21:24","pubTimestamp":1764249856,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that, as of the date of this announcement, it has granted 1.3045 million restricted share units under the 2022 Restricted Share Unit Plan to 146 selected...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1161","06855","BK4139","BK1574"],"gpt_icon":0},{"id":"1126789920","title":"Hong Kong Stock: ASCENTAGE-B Rises Over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126789920","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126789920?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:21","pubTimestamp":1764127283,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855.HK) surged more than 3% in Hong Kong trading. At the time of writing, the stock was up 3.04% to HK$64.35, with a turnover of HK$46.05 million.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","AAPG","06855","BK4139"],"gpt_icon":0},{"id":"1182587677","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182587677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182587677?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:00","pubTimestamp":1764126017,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","AAPG","BK1161","BK4139"],"gpt_icon":0},{"id":"2586341936","title":"Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586341936?lang=en_us&edition=fundamental","pubTime":"2025-11-25 08:00","pubTimestamp":1764028800,"startTime":"0","endTime":"0","summary":"Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3193993/0/en/Ascentage-Pharma-Announces-Publication-of-Olverembatinib-Phase-Ib-Safety-Efficacy-and-Novel-Mechanism-Data-in-Gastrointestinal-Stromal-Tumors-in-Nature-s-Signal-Transduction-and-Ta.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","LU1223083913.SGD","LU1223082519.USD","AAPG","ORR","BK4017","BK4139","LU1223082196.USD"],"gpt_icon":0},{"id":"2585246494","title":"Ascentage Pharma initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2585246494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585246494?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987446,"startTime":"0","endTime":"0","summary":"Truist analyst Gregory Renza initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $51 price target The company’s Lisaftoclax is diff...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2584949009","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949009","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949009?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov.  19, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190863/0/en/Ascentage-Pharma-to-Participate-in-Three-Upcoming-Investor-Conferences-in-December-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}